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Introduction
The majority of bladder cancer patients (around 
75%) initially present with nonmuscle-invasive 
bladder cancer (NMIBC). The standard treatment 
consists of a transurethral resection, followed by 
adjuvant intravesical chemo- or immunotherapy. 
The exact scheme depends on the patient’s risk 
category of recurrence and progression.1
The high recurrence and progression rates2,3 neces-
sitate a high frequency of follow up and consequent 
treatments, imposing a significant financial and 
logistic burden to the patient and to the healthcare 
system. This underlines the need for improved 
treatment, either replacing transurethral resection 
or as a neoadjuvant or adjuvant treatment.
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Abstract
Background: We investigated a thermoreversible hydrogel that is highly viscous at body 
temperature, while fluid-like at a low temperature, thus aiming for a slow and prolonged 
intravesical drug release. Our study purposed to assess antitumor efficacy of mitomycin C 
(MMC) mixed with hydrogel in an orthotopic rat bladder cancer model.
Methods: Bladders of female Fischer F344 rats were grafted with 1.5 × 106 AY-27 urothelial 
carcinoma cells. On day 5, tumor presence was assessed by cystoscopy and rats were divided 
into six groups (five treatment, one control, n = 10/group). Intravesical treatments (0.5 mg or 
1 mg MMC-H2O or MMC-hydrogel, or 2 mg MMC-hydrogel) were administered on days 5, 8 and 
11. Rats were sacrificed at day 14 and bladders were evaluated.
Results: Rats with tumor at cystoscopy (47/60) were evaluated for efficacy. At necropsy, all 
control animals (8/8) had tumors. No microscopic tumors were present in the 0.5 mg and 1 
mg MMC-hydrogel groups compared with 2/8 and 1/8 rats in the 0.5 mg and 1 mg MMC-H2O 
groups (p = 0.47 and p = 1.00, respectively).
Greater toxicity was seen in animals treated with MMC-hydrogel compared with MMC-H2O, as 
demonstrated by lower body weights at necropsy (p = 0.000) and a tendency for more severe 
clinical signs in the 1 and 2 mg MMC-hydrogel groups. Rats that died prematurely received 1 
mg (4/10) or 2 mg (9/10) of MMC-hydrogel.
Conclusions: Under the current model conditions it is unclear whether instillation of MMC-
hydrogel is more effective than MMC-H2O. Nonetheless, the observed difference in toxicity, 
acting as a surrogate marker for systemic MMC exposure in the MMC-hydrogel-treated rats, 
supports the prolonged drug release mechanism of the hydrogel.
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A thermosensitive drug retention system was 
developed for the delivery of various therapeutic 
agents into body internal cavities. This system 
consists of a biocompatible sterile hydrogel which 
has high viscosity (gel state) at body temperature 
and low viscosity (liquid state) at a lower tem-
perature. The liquid state enables the mixing of 
the hydrogel with a specific drug, such as mito-
mycin C (MMC), and facilitates delivery through 
a catheter into the bladder. The solid state ena-
bles an extended dwell time of the hydrogel 
mixed with the drug and hence a prolonged 
exposure of the bladder tissue to MMC with pos-
sibly a higher efficacy.
Typically, water-dissolved MMC is maintained 
intravesically for as long as the patient can 
refrain from urinating. The patient’s urge of uri-
nation, which might be increased in response to 
irritation by MMC, limits the exposure time to 
the drug. Moreover, drug concentration is 
reduced due to continuous urine production. 
Prolonged exposure of the tumor to MMC 
might be more effective and previous studies 
have shown that increased dwell time of MMC 
can significantly increase MMC efficacy in vitro 
and in vivo.4,5
In a limited number of preclinical studies with 
hydrogels, all with different physical character-
istics,6–12 materials were combined with nano-
particles,6,12 epirubicin,7 doxorubicin10 and 
bacillus Calmette-Guérin (BCG).11 These 
studies suggested prolonged exposure or 
enhanced drug penetration.6,7,11,12 The two 
studies evaluating a thermosensitive hydrogel 
different from our thermosensitive hydrogel, 
suggested higher antitumor efficacy based on 
prolonged drug exposure and increased drug 
concentrations6,7,11 or stronger immune 
response if combined with BCG11 as compared 
with standard drug instillations. We therefore 
hypothesized that our thermosensitive MMC-
hydrogel combination will enable longer expo-
sure of the drug to the bladder wall and will 
consequently result in a deeper MMC penetra-
tion and a better oncologic outcome versus 
standard MMC instillations in water.
The aim of our study was to evaluate the efficacy 
of repeated instillations of MMC mixed with the 
thermosensitive hydrogel versus repeated instilla-
tions of MMC in water in an orthotopic AY-27 
rat bladder cancer model.
Methods
To our knowledge, no studies on any hydrogel in 
bladder cancer patients have been published. 
Since no tumor models are available in pigs and a 
good preclinical rat model exists, we chose to use 
the previously described orthotopic AY-27 rat 
bladder cancer model.13–15
Animals
Animal procedures were approved by the 
Institutional Animal Care and Use Committee 
(IACUC, Radboud University Medical Center, 
Nijmegen, The Netherlands) and in compliance 
with European regulations. In total, 60 female 
Fischer F344 rats (Charles River Laboratories 
B.V., Leiden, The Netherlands) weighing 132–
164 g were housed in shared type 3 individually 
ventilated cages (Bleuline series, Techniplast, 
Milan, Italy) with paper bedding (SPPS, Frasne, 
France) and environmental enrichment (2–3 rats/
cage), in a temperature controlled environment 
(19–22°C) with a 12-h light/dark cycle and free 
access to standard chow and water. After treat-
ment allocation, animals were housed according 
to their treatment group to prevent cross-contam-
ination of MMC. General wellbeing, weight and 
clinical signs for humane endpoints were 
monitored.
Tumor cell line
The AY-27 urothelial carcinoma cell line was 
established previously.13 The AY-27 cells were 
grown as a monolayer culture in RPMI-1640 
medium with L-glutamine, supplemented with 
10% fetal bovine serum, 100 U/ml penicillin G, 
and 100 µg/ml streptomycin at 37°C in a humidi-
fied 95% air/5% carbon dioxide atmosphere. Cells 
were passaged using trypsin/0.05% ethyl-enediami-
netetraacetic acid (Life Technologies, Bleiswijk, 
The Netherlands).
Tumor cell implantation
The instillation procedure was performed as 
described previously.13,16 All procedures were per-
formed under inhalation anesthesia. The rat blad-
der was catheterized with a 17-gauge intravenous 
cannula (BD Biosystems, Erembodegem-Aalst, 
Belgium) and drained. The bladder was precondi-
tioned by instillation of 0.4 ml 0.1 M hydrochloride 
for 15 s followed by 0.4 ml 0.1 M potassium 
hydroxide for 15 s. The bladder was drained and 
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flushed three times with 0.8 ml 0.01 M phosphate-
buffered saline. Freshly harvested AY-27 cells (1.5 
× 106 cells in 0.5 ml medium, time between cell 
harvest and bladder inoculation <1 h) were directly 
instilled via the catheter and left indwelling for 60 
min. In order to distribute the cells homogeneously 
over the stripped bladder wall, animals were rotated 
every 15 min. After 1 h the catheter was removed 
and rats were allowed to void spontaneously.
Tumor assessment
Previous studies have demonstrated tumor 
growth in approximately 80% of the animals 5 
days after tumor cell implantation.14–16 To pre-
vent uneven distribution of animals with differ-
ently sized tumors or without any tumor growth 
at all, macroscopic tumor growth was assessed by 
cystoscopy prior to the first treatment at day 5. A 
semi-flexible sialo-endoscope (Erlangen, Karl 
Storz, Tuttlingen, Germany) with a 1.1 mm 
diameter, 10 cm length, and miniature 0° tele-
scope with working and irrigation channel was 
used. The bladder surface was inspected, and a 
video record and images were taken using TELE 
PACK VET X (Karl Storz, Tuttlingen, Germany). 
Animals were allocated evenly in between treat-
ment groups according to their tumor burden.
Test agents
The thermosensitive hydrogel (TC-3 sterile 
hydrogel) and MMC in mannitol (Accord 
Healthcare, Durham, NC, USA) were supplied 
by UroGen Pharma Ltd. (Ra’anana, Israel). 
Dosages were calculated based on the rat bladder 
instillation volume and bladder surface compared 
with the human values, resulting in a respective 
ratio of 106.7 and 22.5. These ratios resulted in a 
respective 40 mg human dose-equivalent of 
0.375–1.78 mg in rats. Based on the latter, the 
chosen low dose in the current study was 0.5 mg.
Prior to each instillation, solutions were prepared 
after liquidation in ice, and were stored protected 
from light at room temperature. For the MMC-
H2O groups, MMC in mannitol was dissolved as 
per the manufacturer’s instruction in sterile water 
to result in a similar osmolality as the saline con-
trol group.
Experimental groups
The estimated response rate to MMC was 60–
70%. We choose an α = 0.05 and a power of 
80%, resulting in a C value of 7.85. Thus, the 
number of animals to be tested was given by (for 
continuous variables of studies comparing two 
means): n = 1 + 2C (s/d)2, where s/d = 0.65 
(mean between 60–70% response rate).
This results in a number of animals needed per 
treatment group of 1 + 2 × 7.85 × (0.65)2 = 7.6 
animals. Thus, eight tumor-positive animals per 
group were needed. To correct for the tumor take 
of 80% at 5 days after tumor cell implantation, a 
factor of 1.25 had to be applied to the amount of 
tumor-bearing animals to calculate the total 
amount of animals per group. Thus, 10 animals 
per group were included.
Rats were treated with a volume of 0.6 ml of test 
agent. Bladder instillations were given on days 5, 
8 and 11 after cell inoculation, using an 18 or 
22-gauge intravenous cannula (BD Biosystems, 
Erembodegem-Aalst, Belgium), which depended 
on the ease of catheterization. During 12 min, 
rats underwent 90° position changes every 4 min. 
Subsequently, the catheter was removed and the 
rats were allowed to void spontaneously. Water 
was withheld for 4 h post-instillation.
The time points were chosen based on our experi-
ence with the orthotopic bladder cancer rat 
model.15,16 It was previously shown that 3–5 days 
after tumor cell inoculation 80% of the rats will be 
tumor-bearing and tumors generally are nonmuscle 
invasive.15 After 5 days, tumors tend to grow into 
the detrusor muscle. Moreover, 5 days post tumor 
implantation the urothelium barrier will have had 
sufficient time to recover from the aggressive pre-
conditioning with HCl for tumor cell implantation. 
Therefore, the first treatment was set on day 5. 
Additionally, the maximum acceptable humane 
endpoint time in this bladder cancer model is 
around 17 days.15 To prevent death due to aggres-
sive tumor growth, 14 days after inoculation was 
chosen as the end-of-experiment time point for 
both ethical and methodological considerations. 
We chose to perform three instillations with equal 
intervals within this time frame of 5–14 days after 
tumor cell inoculation, resulting in 2-day intervals 
and additional instillations at days 8 and 11.
Treatment groups consisted of: (a) NaCl 0.9% as 
control, (b) 0.5 mg MMC-H2O (0.833 mg/ml), (c) 
1 mg MMC-H2O (1.67 mg/ml), (d) 0.5 mg MMC-
hydrogel (0.833 mg/ml), (e) 1 mg MMC-hydrogel 
(1.67 mg/ml), and (f) 2 mg MMC-hydrogel (3.34 
mg/ml). The latter group was added since lower 
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MMC availability could have been a possible sce-
nario for the hydrogel groups and thus it was 
expected that in such case a higher concentration of 
MMC in hydrogel would be needed to reach the 
equivalent mucosal concentration and efficacy as 
compared with MMC administered in H2O. A 
control group with hydrogel only was not included, 
since previous in vivo models have shown good bio-
compatibility of hydrogel in pigs: no toxicity was 
observed after hydrogel only in two previous in vivo 
safety studies in the porcine upper urinary tract.8,9 
These studies report no mortality, clinical adverse 
events, nor meaningful changes in hematology with 
either MMC-hydrogel, hydrogel alone,8,9 or saline.9 
The levels of leucocytes, platelets and the hemato-
crit after hydrogel alone were similar to the sterile 
water group9 or low dose MMC-hydrogel groups.8 
All animals from the different groups gained weight 
at approximately similar rates over the 3 or 6-week 
dosing schedule.8,9 In view of the available evidence 
and in line with the 3R principles no hydrogel-
alone group was included, thus saving animals.8,9
To prevent dehydration, animals received wet food 
when indicated. In reaction to unanticipated signs 
of dehydration, rats from groups e and f were given 
2 ml of NaCl 0.9% subcutaneously twice daily 
from their second treatment and onwards to pre-
vent and treat dehydration. No such signs were 
observed in the MMC-H2O groups.
Blood samples from a subset of rats [n = 5 (groups 
c–e); n = 4 (groups a–b); n = 3 (group F)] were 
collected to assess myelosuppression as a possible 
sign of systemic MMC toxicity after clinical toxic-
ity was observed in some of the first rats.
Necropsy
At day 14, surviving rats were sacrificed by car-
bon dioxide inhalation and necropsy was per-
formed. Bladders were harvested for 
histopathologic examination, as were any other 
macroscopically abnormal tissues. Animals that 
died prior to scheduled necropsy were identi-
cally evaluated. Bladder tissue was weighed, 
fixed and embedded in paraffin. A total of three 
sections of 4–5 µm were cut and stained with 
Haematoxylin-Eosin. Pathologic outcome 
assessment was blinded. A total of two observers 
(HES, specialized uropathologist, and FJPvV) 
evaluated tumor presence, including the number 
of tumors, tumor size, stage, and grade. The 
bladder wall thickness was measured at ⩾1 mm 
distance of any present tumor. Inflammation 
and presence of epithelial atypia were quantified 
and graded as: no reaction, mild, moderate or 
severe reaction. Additionally, presence of hyper-
plasia, denudation, fibrosis, necrosis, edema, or 
hemorrhage was assessed.
Statistics
Fisher’s exact test was used to compare the treat-
ment effect on tumor presence (i.e. for comparing 
proportions). Independent student’s t test was 
used to compare means if a single comparison 
was made. Comparison of multiple means was 
performed by one-way analysis of variance 
(ANOVA) with post-hoc analysis (Tukey HSD or 
Tamhane, depending on assumption of homoge-
neity of variances).
All analyses were performed using SPSS software, 




At 5 days after cell seeding, cystoscopy revealed 
tumors in 78% (47/60) of rats (Figure 1). After 
distribution between the different treatment 
groups, all groups contained 8/10 rats with cys-
toscopy-identified tumors, except for the 0.5 mg 
MMC-hydrogel group which contained 7/10 
tumor-bearing rats. A large diversity of lesions 
was observed on cystoscopy, ranging from 1 or 2 
small lesions to more than five small lesions (<0.5 
mm) or even big lesions (>2.5 mm) per animal. 
No stone formation or inflammation was identi-
fied in any of the rats.
Efficacy
Rats with cystoscopy-identified tumor presence 
(n = 47) were used for the efficacy analysis.
Tumor frequency, stage and grade are shown in 
Table 1. All cystoscopy tumor-positive animals 
from the untreated control group had confirmed 
tumor presence at necropsy (8/8). A total of three 
tumors were detected in the MMC-H2O treated 
groups (b: 2/8; c: 1/8), while no tumors were 
detected in the identical dose MMC-hydrogel 
treatment groups (d: 0/7; e: 0/8). Comparison of 
the number of tumor-positive animals between 
the same MMC dosage in water versus MMC-
hydrogel did not reveal a significant difference (p 
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= 0.47 for 0.5 mg MMC, p = 1.00 for 1 mg 
MMC). In two rats treated with 2 mg MMC-
hydrogel, tumors were found (2/8). Of these ani-
mals, one did not receive the third treatment 
since it was euthanized on day 10 due to severe 
clinical signs, whereas the other was similarly 
euthanized at day 13. No metastasis was observed 
during gross examination at the day of necropsy.
Histopathology
The mean bladder weight of rats treated with 
MMC-H2O (combined groups b + c) was signifi-
cantly lower compared with the bladder weight of 
rats treated with MMC-hydrogel in the same con-
centrations (combined groups d + e) (mean 
0.221 g versus 0.266 g, p = 0.01). No significant 
differences were seen between the treatment 
groups regarding the presence of epithelial atypia, 
hyperplasia, denudation, inflammation, fibrosis 
or necrosis. Epithelial atypia was considered as 
being reactive atypia to MMC exposure, not as 
carcinoma in situ. None of the rats in the control 
group (n = 10) had epithelial atypia. A gradual 
increase in bladder wall thickness was seen with 
increasing MMC dose, independent of the vehi-
cle used. None of the bladders showed signs of 
perforation. Hemorrhage was seen in 23 rats and 
was abundant in group f (9/10).
Animal wellbeing
Animal weights decreased significantly during 
treatments [Figure 2(a)], with MMC treatment 
Figure 1. Tumor take as judged on cystoscopy.
Overall, three images are depicted with a solitary tumor (left image, arrow), multiple tumors (center image, arrows), and no 
tumor on cystoscopy (right image).
Table 1. Number of rats with tumors found on microscopic evaluation.
Group MMC dosage (mg) Vehicle No. of rats with tumor 
(n/group size)
T stage†
a 0 NaCl 0.9% 8/8 T2 (4/8), T3a (4/8)
b 0.5 H2O 2/8 T2 (2/2)
c 1.0 H2O 1/8 T1 (1/1)
d 0.5 Hydrogel 0/7* NA
e 1.0 Hydrogel 0/8**,‡ NA
f 2.0 Hydrogel 2/8 ¶ T1 (1/8), T2 (1/8)
MMC, mitomycin C; NA, not applicable.
*Fisher exact test for comparison of the 0.5 mg MMC dose in H2O and hydrogel groups: p = 0.467.
**Fisher exact test for comparison of the 1 mg MMC dose in H2O and hydrogel groups: p = 1.000.
†All tumors found on microscopy (n = 13) were grade 3 (high grade) transitional cell carcinomas.
‡Three rats were killed before the predetermined endpoint as they reached a predefined humane endpoint: day 12 (n = 1) 
and day 13 (n = 2). In addition, one rat was found dead at day 13.
¶Five rats were killed before the predetermined endpoint as they reached a predefined humane endpoint: day 12 (n = 
1) and day 13 (n = 4). In addition, at day 10 one rat was found dead after completing 2/3 treatments only), and three rats 
were found dead at day 13.
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leading to a dose-dependent significant lower 
body weight [mean body weight at necropsy 153 
g (group a) versus 124 g (groups b–f), p = 0.000]. 
When MMC-hydrogel was administered (groups 
d + e), animal weight decreased significantly 
compared with MMC-H2O (groups b + c) 
[Figure 2(b); mean weight at necropsy 140 g ver-
sus 121 g, p = 0.000].
A total of eight rats were killed prematurely 
because they reached the predefined humane 
endpoints (i.e. weight loss of >20% of weight at 
start, or clinical signs of failure to thrive); five rats 
were found dead (Table 1). At necropsy, nonhe-
matologic changes were observed in seven rats 
and included a dilated ureter or kidney (n = 3), 
pelvic inflammation (n = 2), microscopic intersti-
tial hemorrhage (n = 2), and intestinal necrosis 
(n = 3, all found dead without known time of 
death). These effects were equally seen in the 
MMC-H2O and MMC-hydrogel treated groups. 
Thus, they were most likely model-related and 
might have been due to the frequent invasive 
therapeutic procedures, transient obstruction or 
reflux of the instilled fluid into the upper urinary 
tract, or due to the MMC instillation itself. 
Although pelvic inflammation and intestinal 
necrosis might be signs of bladder perforation, no 
signs of perforation were found on pathologic 
assessment of the bladders.
A reluctance to consume food and water was 
noticed in all rats receiving MMC-hydrogel from 
day 11 onwards. Clinical signs seemed to be more 
severe at higher MMC doses or when MMC-
hydrogel was used and were typical for MMC-
induced effects. No adverse events were observed 
in the saline control group.
The mean number of erythrocytes, leucocytes 
and amount of hemoglobulin was not significantly 
different between treatment groups (one-way 
ANOVA p > 0.05 in all), although a trend for 
lower levels in the hydrogel group was observed. 
However, mean thrombocyte count differed sig-
nificantly between control and the higher dose 
Figure 2. Toxicity in the different treatment groups.
All error bars represent 95% confidence intervals. (a) mean animal weight per treatment group, (b) mean animal weight 
of MMC-H2O (groups b + c) versus MMC-hydrogel (groups d + e) treated rats (*, p < 0.05), (c) dot plot of the mean level of 
thrombocytes per group (*, p = 0.001; **, p = 0.000 compared with control). The number of animals evaluated in figure (c): 
groups a, b; n = 4, groups c–e; n = 5, group f; n = 3.
MMC, mitomycin C.
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MMC-hydrogel treated rats (for respectively 
group e and f: mean 564 × 109/l versus 161 × 
109/l, p = 0.001; and 564 × 109/l versus 9.3 x× 
109/l, p = 0.000;) [Figure 2(c)]. Consequently, 
systemic MMC-induced myelosuppression was 
assumed.
Discussion
We hypothesized that extended release of MMC 
from a thermosensitive hydrogel would lead to 
higher cure rates in this orthotopic bladder cancer 
rat model. Treatment was highly effective in all 
the animals treated with MMC, both with and 
without hydrogel, regardless of the MMC dose 
used. No significant difference in efficacy was 
found following treatment of MMC-hydrogel ver-
sus MMC-H2O. The reason for the high efficacy 
regardless of the vehicle used may be the high 
administered MMC concentrations. However, we 
did observe more systemic toxicity in the animals 
treated with MMC-hydrogel compared with 
MMC-H2O, especially at the higher MMC dos-
ages. MMC-hydrogel treatment resulted in sig-
nificantly lower thrombocyte levels in the 1 mg 
and 2 mg MMC-hydrogel groups compared with 
the saline control group, accompanied by a signifi-
cantly lower body weight at necropsy. Body weight 
was also significantly lower when MMC-hydrogel 
was compared with MMC-H2O. All rats that died 
prior to necropsy belonged to the 1 mg and 2 mg 
MMC-hydrogel groups. The enhanced toxicity in 
animals treated with MMC-hydrogel is possibly 
caused by the longer intravesical drug residence 
time, leading to extended MMC exposure locally 
and systemically. Due to the slow dissolution of 
the MMC-containing hydrogel, the bladder 
mucosa is exposed to MMC for as long as the gel 
is not fully dissolved and removed from the blad-
der through micturition (an estimated period of 
1–3 h in rats, data not shown). We hypothesize 
that the prolonged exposure of the mucosa to 
MMC resulted in significantly higher levels of sys-
temic MMC in rats and eventually in myelosup-
pression causing the clinical signs, weight loss and 
preliminary death, acting as a surrogate biomarker 
for MMC exposure. Thus, despite our failure to 
show higher efficacy, our results suggest that 
encapsulation of MMC in this hydrogel results in 
increased MMC tissue exposure.
Remarkably, prolonged exposure to similar or 
considerably higher concentrations of MMC-
hydrogel of the renal pelvis in other animals (up 
to 8 mg/ml in pigs)8,9 or bladder mucosa in 
NMIBC patients (conference abstract17), did not 
result in enhanced systemic toxicity. Moreover, 
plasma MMC levels were low and several orders 
of magnitude below levels known to be associated 
with systemic toxicity.18 This suggests that MMC-
related toxicity may be species specific. Indeed, 
Vandepitte and colleagues reported that rats are 
more sensitive to MMC.19 In the same orthotopic 
rat bladder tumor model as used in our study, rats 
were treated with either a single instillation of 1 
mM MMC (0.334 mg/ml) or 10 mM MMC 
(3.34 mg/ml) for 2 h one day after tumor cell 
implantation. From the five rats treated with 10 
mM MMC, a concentration identical to our high-
est MCC dose group, none survived more than 7 
days, most likely due to a systemic toxic effect of 
the MMC.19 Although a single instillation was 
given, MMC remained longer intravesically, and 
the interval between mucosa preconditioning 
with HCl and treatment was much shorter com-
pared with our treatment schedule. As the barrier 
function of the urothelium is impaired after pre-
conditioning, this could have contributed to the 
observed systemic MMC toxicity in their experi-
ment. We have allowed the urothelium to recover 
for 5 days, and administered three treatments 
with the highest dose (3.34 mg/ml MMC) which 
might have been a too intense dosing schedule for 
the already thin rat bladder wall. In line with the 
presumed prolonged MMC exposure, the 
increased bladder wall contact time might explain 
the increased bladder weight secondary to any 
local irritation, inflammation, edema, fibrosis, or 
potential immune-stimulatory effects of the 
MMC-hydrogel.
No direct data such as plasma and tissue concen-
trations of MMC are available to support our sug-
gestion that the higher toxicity observed in the 
MMC-hydrogel group is a consequence of pro-
longed exposure to MMC. This enhanced toxic-
ity was unanticipated. As such, no blood or tissue 
samples for assessment of MMC concentrations 
were collected since our primary goal was to eval-
uate efficacy. However, indirect evidence is highly 
suggestive: all observed toxicity and clinical 
symptoms were typical for MMC-induced effects. 
The thrombocyte levels decreased, animals expe-
rienced severe weight loss, and animals died pre-
maturely in the MMC-hydrogel groups. This 
toxicity appeared to be dose-dependent within 
the different vehicles, which was in accordance 
with previous porcine models.8,9 Any procedural 
influence on the toxicity (e.g. catheterization, 
instillation) is unlikely in view of the saline 
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control group and by previous studies using the 
same methodology.14–16,19 Perforation or exces-
sive inflammatory response was excluded by 
extensive pathologic assessment of the bladders. 
Thus, the remaining factor for explaining the 
observed premature deaths, weight loss, and tox-
icity in the MMC-hydrogel groups is an increased 
bladder wall contact time with MMC leading to a 
too high systemic exposure of MMC with our 
chosen concentration of MMC.
The conditions in this model seem suboptimal to 
investigate whether this new treatment of urothe-
lial carcinoma was superior. This may have been 
caused by: (1) use of a too high dose of MMC 
resulting in only few tumors present at necropsy 
in both the MMC-hydrogel and, specifically, 
MMC-H2O groups to demonstrate a potential 
difference in efficacy, (2) a too high treatment fre-
quency and too small intervals between treat-
ments that prevented sufficient recovery of 
animals following each treatment (typically, an 
induction course in humans consists of six treat-
ments weekly), or (3) a too low animal weight at 
study onset, associated with a small bladder size, 
and possibly with a relatively too high instillation 
volume of the hydrogel which might have led to 
volumetric obstruction. In previous in vivo safety 
studies, no toxicity was observed after hydrogel 
instillation in the porcine upper urinary tract.8,9 
Based on these observations and in line with the 
3R principle, a hydrogel-alone group was not 
included in the present study. Nevertheless, the 
collective evidence suggests that direct and indi-
rect effects on the bladder wall are likely a conse-
quence of MMC and not of the hydrogel.
In conclusion, a prolonged exposure of the 
tumor to the drug-containing hydrogel is sug-
gested by the observed enhanced toxicity, acting 
as a surrogate marker for MMC exposure. 
Treatment with the tested doses of intravesical 
MMC using either vehicle was highly effective, 
although the MMC-hydrogel was toxic to rats at 
the levels administered. Whether MMC-
hydrogel is more efficacious than MMC-H2O 
could not be determined due to too high MMC 
dosing and low tumor frequencies following 
either treatment. We hypothesize that in light of 
a prolonged exposure, the hydrogel might main-
tain or ideally even improve treatment efficacy in 
rats compared with aqueous MMC when lower 
doses of drug are used. This might create oppor-
tunities in the treatment of bladder or, espe-
cially, upper urinary tract urothelial carcinomas, 
where instillations are suboptimal due to the 
swift washout of the instilled fluid. However, 
confirmation of improved or similar efficacy 
together with similar or decreased toxicity of 
lower dosed MMC-hydrogel is needed.
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